Eli Lilly: positive trials in type 2 diabetes
In target-therapy clinical trials, efsitora showed a non-inferior reduction in A1C compared with the world's most commonly used daily basal insulins.
' The results [from the two trials] are an important milestone for the diabetes community and demonstrate that efficacy as a weekly insulin provides equivalent glycemic control to daily basal insulins', said Jeff Emmick, MD, Ph.D., senior vice president, product development, Lilly.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction